Marshall Wace, LLP Vaxart, Inc. Call Options Transaction History
Marshall Wace, LLP
- $81.7 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VXRT
# of Institutions
105Shares Held
23.1MCall Options Held
50.3KPut Options Held
0-
Vanguard Group Inc Valley Forge, PA10.4MShares$3.96 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.33MShares$884,0200.0% of portfolio
-
Black Rock Inc. New York, NY1.77MShares$674,2510.0% of portfolio
-
State Street Corp Boston, MA851KShares$323,4250.0% of portfolio
-
Ubs Group Ag826KShares$313,7880.0% of portfolio
About Vaxart, Inc.
- Ticker VXRT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,506,000
- Market Cap $48.1M
- Description
- Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...